ALBO - Albireo Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.74
+0.05 (+0.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close24.69
Open24.68
Bid20.16 x 900
Ask25.94 x 800
Day's Range24.61 - 25.08
52 Week Range16.13 - 38.69
Volume74,182
Avg. Volume110,045
Market Cap368.064M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-5.80
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.17
  • GlobeNewswire

    Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. In addition, the underwriters have exercised in full an option to purchase an additional 285,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $46.0 million and net proceeds of approximately $42.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.

  • GlobeNewswire

    Albireo Prices $40 Million Public Offering of Common Stock

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. Albireo’s gross proceeds from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 285,750 shares of common stock on the same terms and conditions.

  • GlobeNewswire

    Albireo Announces Proposed Public Offering of Common Stock

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering. All of the shares in the offering will be sold by Albireo.

  • GlobeNewswire

    Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once-daily capsule in development for the treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. The U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application to initiate a global pivotal trial in biliary atresia.

  • GlobeNewswire

    Albireo Joins with Alagille Syndrome Community in Celebrating First International Awareness Day

    Alagille syndrome community advocates for education and resources with first-ever disease awareness day. BOSTON, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille Awareness Day on January 24, 2020, acknowledging pediatric hepatologist and researcher Dr. Daniel Alagille, who first characterized the syndrome. Alagille syndrome (ALGS) is a rare genetic disorder associated with liver, heart, eye and skeletal abnormalities without an approved pharmacological treatment.

  • Do Hedge Funds Love Albireo Pharma, Inc. (ALBO)?
    Insider Monkey

    Do Hedge Funds Love Albireo Pharma, Inc. (ALBO)?

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • Barrons.com

    Biotech Stocks Are In a Position to Break Out in 2020, Analysts Say

    Biotech surged in the third quarter, approvals from the Food & Drug Administration are coming through above the average annual rate, the valuation of large-cap biotechs are attractive, and there have been significant mergers and acquisitions in past years.

  • Is Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Salary Justified?
    Simply Wall St.

    Is Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Salary Justified?

    Ron Cooper became the CEO of Albireo Pharma, Inc. (NASDAQ:ALBO) in 2015. This report will, first, examine the CEO...

  • GlobeNewswire

    Albireo to Present at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 14, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

  • Were Hedge Funds Right About Souring On Albireo Pharma, Inc. (ALBO)?
    Insider Monkey

    Were Hedge Funds Right About Souring On Albireo Pharma, Inc. (ALBO)?

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • GlobeNewswire

    Albireo Reports Third Quarter 2019 Financial Results and Provides Business Update

    — Phase 3 PFIC trial randomization more than three-quarters complete. —— Topline results expected mid-2020. —— Pivotal trial in biliary atresia expected to be initiated in 2020..

  • GlobeNewswire

    Albireo Appoints Michelle Graham as Chief Human Resources Officer

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Michelle Graham has been appointed Chief Human Resources Officer, effective today. “We are delighted attract Michelle to Albireo during this pivotal period. “We are creating something special at Albireo, and our employees’ incredible work has accelerated our progress.

  • Will Albireo Pharma (NASDAQ:ALBO) Spend Its Cash Wisely?
    Simply Wall St.

    Will Albireo Pharma (NASDAQ:ALBO) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Albireo to Report Third Quarter 2019 Financial Results on November 6, 2019

    BOSTON, Oct. 30, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

  • GlobeNewswire

    Albireo Recognizes PFIC Awareness Day and Highlights Urgent Needs of Progressive Familial Intrahepatic Cholestasis Families

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today its support for PFIC Awareness Day, and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC). PFIC is an ultra-rare, life-threatening, pediatric liver disease characterized by pruritus (intense itching), jaundice (elevated serum bilirubin levels that may manifest as yellowing of the skin), and poor weight gain and growth. People with PFIC are often diagnosed in infancy or early childhood and can progress to cirrhosis and liver failure by age 10 without surgical intervention.

  • GlobeNewswire

    Albireo Announces Presentations at NASPGHAN 2019 Annual Meeting

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced upcoming presentations at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2019 Annual Meeting, being held October 16-19, 2019, in Chicago. The presentations will include pharmacological data regarding the Company’s lead product candidate, odevixibat, as well as background about the Company’s proprietary patient- and observer-reported outcomes assessment tools for pruritus. “When considering existing and emerging pediatric therapies, there is a strong desire among physicians, parents and patients for exposure levels to be concentrated in targeted areas of the body while minimizing broader systemic exposure,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • Is Albireo Pharma, Inc. (NASDAQ:ALBO) A Volatile Stock?
    Simply Wall St.

    Is Albireo Pharma, Inc. (NASDAQ:ALBO) A Volatile Stock?

    If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...

  • GlobeNewswire

    Albireo to Participate in Upcoming Investor Conferences

    BOSTON, Sept. 03, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

  • Albireo Pharma, Inc. (ALBO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Albireo Pharma, Inc. (ALBO) Q2 2019 Earnings Call Transcript

    ALBO earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Albireo Reports Second Quarter 2019 Financial Results

    — Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 —— Initiated elobixibat Phase 2 trial in NAFLD/NASH —— Management to host conference call and webcast today at 10.

  • GlobeNewswire

    Albireo to Present at Wedbush PacGrow Healthcare Conference

    BOSTON, Aug. 06, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

  • GlobeNewswire

    Albireo to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast

    BOSTON, Aug. 01, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

  • Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for

    Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Albireo Provides Mid-Year Clinical Development Update

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH. The odevixibat PEDFIC program in progressive familial intrahepatic cholestasis (PFIC) consists of two clinical trials.